Previous Article | Next Article ![]()
J. Virol., Nov 1995, 6911-6916, Vol 69, No. 11
VV Lukashov, CL Kuiken and J Goudsmit
The antigenic diversity threshold theory predicts that antigenic sites of
human immunodeficiency virus type 1, such as the V3 region of the external
glycoprotein gp120, evolve more rapidly during the symptom- free period in
individuals progressing to AIDS than in those who remain asymptomatic for a
long time. To test this hypothesis, genomic RNA sequences were obtained
from the sera of 44 individuals at seroconversion and 5 years later. The
mean number of nonsynonymous nucleotide substitutions in the V3 region of
the viruses circulating in 31 nonprogressors (1.1 x 10(-2) +/- 0.1 x 10(-2)
per site per year) was higher than the corresponding value for 13
progressors (0.66 x 10(-2) +/- 0.1 x 10(-2) per site per year) (P <
0.01), while no difference between the mean numbers of synonymous
substitutions in the two groups was seen (0.37 x 10(-2) +/- 0.1 x 10(-2)
and 0.51 x 10(-2) +/- 0.2 x 10(-2) per site per year for nonprogressors and
progressors, respectively; P > 0.1). The mean ratios of synonymous
nucleotide p distance to nonsynonymous p distance were 0.35 for
nonprogressors and 0.62 for progressors. The number of nonsynonymous
substitutions was not associated with virus load or virus phenotype, which
are established predictors of disease progression, but correlated strongly
with the duration of the immunocompetent period (r2 = 0.41; P = 0.001).
This indicates that there is no causative relationship between intrahost
evolution and CD4+ cell decline. Our data suggest that intrahost evolution
in human immunodeficiency virus type 1 infection is driven by selective
forces, the strength of which is related to the duration of the
immunocompetent period.
Copyright © 1995, American Society for Microbiology
Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period
Human Retrovirus Laboratory, University of Amsterdam, The Netherlands.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|